

Karolinska Development AGM 2024: Information on candidates nominated for election or re-election to the board

Re election

Theresa Tse

Board Member since 2017.

Born 1992. Bachelor's Degree of Science in Economics from the Wharton School of University of Pennsylvania.

Other appointments: Chairwoman of the Board and Executive Director of Sino Biopharmaceutical Ltd (listed at the Hong Kong stock exchange) and member of the Board of Directors of invoX Pharma Ltd., France Investment (China 1) Group Limited, Chia Tai Life Technology Limited and Yun On Investment Holding Limited.

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 128,736,384 shares (by related legal person).

Re election

Anna Lefevre Skjöldebrand

Board Member since 2021.

Born 1969. Master of Laws from Uppsala University.

Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (Chairwoman), Swecare and St Eriks ögonsjukhus.

Prior assignments include i.a.: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Previous board assignments include i.a.: Dedicare AB, E-hälsomyndigheten, SIS AB, Medtech Europe and COCIR, Life Science office of Sweden. She has also been a member of the board in the Board for Public Procurement.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Re election

Ben Toogood

Board Member since 2021.

Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.

Other appointments: Head Global Business Development, Sino Biopharmaceuticals Limited, CEO invoX Pharma Limited, Director of Softhale BV and pHion Therapeutics.

Previous assignments include i.a.: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 64,001 shares.

Re election

Philip Duong

Board Member since 2022.

Born 1990. Bachelor's degree of Commerce from University of Toronto.

Other appointments: Head of Overseas BD & Alliance at Sino Biopharmaceuticals Limited, member of the Board of Directors at Treadwell Therapeutics.

Previous assignments include i.a.: Deutsche Bank AG (Hong Kong Branch).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

New election

Hans Wigzell

Born 1938. Professor Emeritus of Immunology and MD.

Other appointments: Chairman of Rhenman & Partner Asset Management AB and RaySearch Laboratories AB. Board member of Sarepta Therapeutics Inc. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences.

Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and president of Karolinska Institutet, director general of Smittskyddsinstitutet and board member/chariman of Karolinska Development AB (publ).

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 1,228,613 shares.